This agent differs from earlier therapies that were designed to reduce myocardial loading or induce neurohumoral blockade
1 2 3 4 Baggio LL, Drucker DJ (May 2007)
Within the last 10 years, the FDA has chronicled manufacturing problems including mislabeling of childrens tablets, where packages of the product listed an incorrect amount of the ingredients per tablet, inadequate cleaning of equipment used for manufacturing, insufficient follow-up in investigating consumer complaints, product mix-ups, and contamination with metal fragments and bacteria
Yes, the dosage and frequency of B12 injections are highly dependent on the severity of the deficiency and the presence of neurological symptoms
Adults with Type 2 diabetes who continued GLP-1 use for the entire 3-year period had a near 20% lower risk of major adverse cardiovascular events
Critically, these reductions werent explained by general sedation or illness the animals remained active and continued eating normally